Design Therapeutics, Inc. (DSGN): Price and Financial Metrics
GET POWR RATINGS... FREE!
DSGN Stock Price Chart Interactive Chart >
DSGN Price/Volume Stats
|Current price||$8.27||52-week high||$26.30|
|Prev. close||$8.49||52-week low||$6.94|
|Day high||$8.63||Avg. volume||438,611|
|50-day MA||$10.56||Dividend yield||N/A|
|200-day MA||$15.05||Market Cap||462.38M|
Design Therapeutics, Inc. (DSGN) Company Bio
Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy. The company was incorporated in 2017 and is based in Carlsbad, California.
Most Popular Stories View All
DSGN Latest News Stream
|Loading, please wait...|
DSGN Latest Social Stream
View Full DSGN Social Stream
Latest DSGN News From Around the Web
Below are the latest news stories about DESIGN THERAPEUTICS INC that investors may wish to consider to help them evaluate DSGN as an investment opportunity.
Independent Director Rodney Lappe Just Bought 15% More Shares In Design Therapeutics, Inc. (NASDAQ:DSGN)
Investors who take an interest in Design Therapeutics, Inc. ( NASDAQ:DSGN ) should definitely note that the Independent...
We're starting off the day with a look at the biggest pre-market stock movers that traders will want to watch on Thursday!
Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress
DT-216 was Generally Well-Tolerated and Resulted in a More than Doubling of Frataxin mRNA in Patients with Friedreich Ataxia Second GeneTACTM Development Candidate, DT-168, Selected for the Treatment of Fuchs Endothelial Corneal Dystrophy Administered as an Eye Drop; IND Expected in 2023 Advancing Myotonic Dystrophy Type-1 GeneTACTM Lead Molecules; IND Expected in 2024 Conference Call to be Held Today at 4:30pm ET CARLSBAD, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nas
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results
Initial Data from Single-Ascending Dose Phase 1 Trial of DT-216 for Friedreich Ataxia Expected to be Reported in December 2022 Dosing Initiated in the Multiple-Ascending Dose Phase 1 Trial of DT-216; Trial Completion Anticipated in Mid-2023 Strong Financial Position with $344.2 Million in Cash and Securities to Support Multi-Year Operating Runway and Further Advancement of GeneTAC™ Platform CARLSBAD, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-s
DSGN Price Returns